| Species |
Human |
| Protein Construction |
IL-17D (Ala18-Pro202)
Accession # Q8TAD2 |
|
| Purity |
> 90% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by gel clotting method |
| Expression System |
CHO |
| Apparent Molecular Weight |
~12.1 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
IL-17D is a secreted cytokine with homology to the IL-17 family of proteins. It is preferentially expressed in skeletal muscle, brain, adipose tissue, heart, lung, and pancreas. It has been reported that IL-17D has the ability to stimulate the production of other cytokines from target tissues such as endothelial cells, treatment of endothelial cells with purified rIL-17D protein stimulated the production of IL-6, IL-8, and GM-CSF. In addition, rIL-17D also demonstrated an inhibitory effect on hemopoiesis of myeloid progenitor cells in colony formation assays. |
| Synonyms |
Interleukin-17D; IL-17D; IL17D |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
